Trial Profile
Withdrawal responses to abiraterone acetate on prostate specific antigen declines in patients with castration resistant prostate cancer (CRPC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Aug 2015
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 19 Aug 2015 New trial record